NEW YORK (GenomeWeb News) – Shimadzu said today that it has registered several of its HPLC and LC-MS instruments as Class I medical devices with the US Food and Drug Administration, allowing them to be used in clinical settings.

The registration covers Shimadzu's LC-20 CL and LC-30 CL HPLCs; LC-MS-2020 CL single quadrupole mass spec; and LC-MS-8030 CL, LC-MS-8040 CL, and LC-MS-8050 CL triple quadrupole mass specs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.